


In the Claims:

1. (Currently Amended): A pharmaceutical composition comprising at least one active compound of formula (I):




(I)

or a pharmaceutically acceptable salt thereof,

wherein

B is cytosine or 5-fluorocytosine, and

R is H, ~~monophosphate, diphosphate, triphosphate, carbonyl substituted with a C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, or C₆₋₁₀-aryl, or~~



~~Re is, in each case independently, H, C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl or a hydroxy protecting group; and~~

the a Bcr-Abl tyrosine kinase inhibitor imatinib mesylate,

~~wherein "alkyl" is unsubstituted or substituted by a halogen, nitro, CONH₂, COOH, O-C₁₋₆-alkyl, O-C₂₋₆-alkenyl, O-C₂₋₆-alkynyl, hydroxyl, amine, or COOQ, wherein Q is C₁₋₆-alkyl, C₂₋₆-alkenyl, or C₂₋₆-alkynyl, and~~

wherein said compound of formula (I) or a pharmaceutically acceptable salt thereof and said Bcr-Abl tyrosine kinase inhibitor are present in a synergistic ratio.

2. (Cancelled):

3. (Cancelled):

4. (Cancelled):

5. (Cancelled):

6. (Cancelled):

7. (Previously Presented): The pharmaceutical composition according to claim 1, wherein the compound of formula I is (-)- β -L-Dioxolane-Cytidine.

8. (Cancelled):

9. (Currently Amended): The pharmaceutical composition according to claim 1, wherein the compound of formula I is substantially in the form of the (-) enantiomer.


10. (Currently Amended): The pharmaceutical composition according to claim 1, wherein said compound of formula (I) is at least 97% free of the corresponding (+) enantiomer.

11. (Cancelled):

12. (Cancelled):

13. (Cancelled):

14. (Currently Amended): A pharmaceutical combination comprising at least one active compound of formula (I):




(I)

or a pharmaceutically acceptable salt thereof,

wherein

B is cytosine or 5-fluorocytosine, and

R is H, ~~monophosphate, diphosphate, triphosphate, carbonyl substituted with a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, or C₆₋₁₀ aryl, or~~




Re is, in each case independently, H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or a hydroxy protecting group; and

the a Bcr-Abl tyrosine kinase inhibitor imatinib mesylate;

~~wherein "alkyl" is unsubstituted or substituted by a halogen, nitro, CONH₂, COOH, O-C₁₋₆ alkyl, O-C₂₋₆ alkenyl, O-C₂₋₆ alkynyl, hydroxyl, amino, or COOQ, wherein Q is C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl, and~~

wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof and the Bcr-Abl tyrosine kinase inhibitor are present in a synergistic ratio.

15. (Currently Amended): A method of treating a patient having leukemia comprising administering to said patient a therapeutically effective amount of a compound of formula I:




or a pharmaceutically acceptable salt thereof,

wherein

B is cytosine ~~or 5-fluorocytosine~~, and

R is H, ~~monophosphate, diphosphate, triphosphate, carbonyl substituted with a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, or C₆₋₁₀ aryl, or~~



Re is, in each case independently, H, C₁₋₆ alkyl,

~~C₂₋₆-alkenyl, C₂₋₆-alkynyl or a hydroxy protecting group, and~~
~~the~~ a Bcr-Abl tyrosine kinase inhibitor imatinib mesylate,

~~wherein "alkyl" is unsubstituted or substituted by a halogen, nitro, CONH₂, COOH, O-C₁₋₆-alkyl, O-C₂₋₆-alkenyl, O-C₂₋₆-alkynyl, hydroxyl, amino, or COOQ, wherein Q is C₁₋₆-alkyl, C₂₋₆-alkenyl, or C₂₋₆-alkynyl, and~~

wherein said compound of formula (I) or a pharmaceutically acceptable salt thereof and said Bcr-Abl tyrosine kinase inhibitor are administered at a synergistic ratio.

16. (Cancelled):

17. (Previously Presented): The method according to claim 15, wherein said patient is suffering from acute myelogenous leukemia.

18. (Previously Presented): The method according to claim 15, wherein said patient is suffering from chronic myelogenous leukemia in blastic phase.

19. (Previously Presented): The method according to claim 15, wherein said patient has refractory / relapsed leukemia.

20. (Previously Presented): The method according to claim 15, wherein said patient has refractory / relapsed leukemia and said patient has been previously treated with imatinib mesylate.

21. (Currently Amended): The method according to claim 15, wherein said patient has refractory / relapsed leukemia, said patient has been previously treated with imatinib mesylate ~~mesylates~~, and said patient is resistant to imatinib mesylate.

22. (Currently Amended): The method according to claim 15, wherein said patient has refractory / relapsed leukemia and said patient has been previously treated with imatinib mesylate ~~mesylates~~, wherein the compound of formula (I) is (-)- β -L-Dioxolane-Cytidine ~~and the Bcr-Abl tyrosine kinase inhibitor is imatinib mesylate~~.

23. (Cancelled):

24. (Cancelled):

25. (Previously Presented): A pharmaceutical composition according to claim 1, further comprising at least one pharmaceutically acceptable carrier or excipient.
26. (Previously Presented): A method according to claim 15, wherein said patient is suffering from chronic myelogenous leukemia.
27. (Previously Presented): A method according to claim 15, wherein said patient is suffering from acute lymphocytic leukemia.
28. (Previously Presented): A method according to claim 15, wherein said patient is suffering from chronic lymphocytic leukemia.
29. (Previously Presented): A method according to claim 15, wherein said patient is suffering from hairy cell leukemia.
30. (Previously Presented): A method according to claim 15, wherein said patient is suffering from acute myelogenous leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, hairy cell leukemia, myelodysplastic syndrome or chronic myelogenous leukemia in blastic.
31. (Currently Amended): A pharmaceutical composition according to claim 1 2, wherein said compound of formula (I) or a pharmaceutically acceptable salt thereof is at least 95% free of the corresponding (+) enantiomer.
32. (Currently Amended): A pharmaceutical composition according to claim 1 2, wherein said compound of formula (I) or a pharmaceutically acceptable salt thereof is at least 99% free of the corresponding (+) enantiomer.
33. (Cancelled):
34. (Cancelled):
35. (Cancelled):
36. (Cancelled):

37. (Cancelled):

38. (Cancelled):

39. (Currently Amended): A method according to claim 15, wherein said compound of formula (I) or a pharmaceutically acceptable salt thereof is administered to said patient at a dose between 1 mg/m^2 and 8 mg/m^2 , and said Bcr-Abl tyrosine kinase inhibitor is administered to said patient at a dose between 0.1 gm/m^2 and 30 gm/m^2 .

40. (Currently Amended): A method according to claim 15, wherein said compound of formula (I) or a pharmaceutically acceptable salt thereof is administered to said patient at a dose between about 1 mg/m^2 and about 8 mg/m^2 , and said Bcr-Abl tyrosine kinase inhibitor is administered to said patient at a dose between 0.1 gm/m^2 and 6 gm/m^2 .

41. (Currently Amended): A method according to claim 15, wherein said compound of formula (I) or a pharmaceutically acceptable salt thereof and said Bcr-Abl tyrosine kinase inhibitor are administered sequentially.

42. (Currently Amended): A method according to claim 15, wherein said compound of formula (I) or a pharmaceutically acceptable salt thereof and said Bcr-Abl tyrosine kinase inhibitor are administered simultaneously in a separate pharmaceutical formulations ~~formulation~~.

43. (Currently Amended): A method according to claim 15, wherein said compound of formula (I) or a pharmaceutically acceptable salt thereof and said Bcr-Abl tyrosine kinase inhibitor are administered simultaneously in a combined pharmaceutical formulation.

44. (Currently Amended): A combination according to claim 14, wherein said compound of formula (I) or a pharmaceutically acceptable salt thereof and said Bcr-Abl tyrosine kinase inhibitor are in separate pharmaceutical formulations.

45. (Currently Amended): A combination according to claim 14, wherein said compound of formula (I) or a pharmaceutically acceptable salt thereof and said Bcr-Abl tyrosine kinase inhibitor are in a combined pharmaceutical formulation.

46. (Currently Amended): A composition according to claim 1, wherein said compound of formula (I) or a pharmaceutically acceptable salt thereof and said Bcr-Abl tyrosine kinase inhibitor are present at a ratio of 1:5 to 1:2.

47. (Currently Amended): A combination according to claim 14, wherein said compound of formula (I) or a pharmaceutically acceptable salt thereof and said Bcr-Abl tyrosine kinase inhibitor are present at a ratio of 1:5 to 1:2.

48. (Currently Amended): A method according to claim 15, wherein said compound of formula (I) or a pharmaceutically acceptable salt thereof and said Bcr-Abl tyrosine kinase inhibitor are administered at a ratio of 1:5 to 1:2.

49. (Currently Amended): A composition according to claim 46, wherein said compound of formula (I) is (-)- β -L-Dioxolane-Cytidine ~~and the Bcr-Abl tyrosine kinase inhibitor is imatinib mesylate.~~

50. (Currently Amended): A combination according to claim 47, wherein said compound of formula (I) is (-)- β -L-Dioxolane-Cytidine ~~and the Bcr-Abl tyrosine kinase inhibitor is imatinib mesylate.~~

51. (Currently Amended): A method according to claim 48, said compound of formula (I) is (-)- β -L-Dioxolane-Cytidine ~~and the Bcr-Abl tyrosine kinase inhibitor is imatinib mesylate.~~

52. (Currently Amended): A method according to claim ~~15~~ 46, wherein said compound of formula (I) is (-)- β -L-Dioxolane-Cytidine ~~and the Bcr-Abl tyrosine kinase inhibitor is imatinib mesylate.~~

53. (Currently Amended): A method according to claim 17, wherein said compound of formula (I) is (-)- β -L-Dioxolane-Cytidine ~~and the Ber-Abl tyrosine kinase inhibitor is imatinib mesylate.~~

54. (Currently Amended): A method according to claim 18, wherein said compound of formula (I) is (-)- β -L-Dioxolane-Cytidine ~~and the Ber-Abl tyrosine kinase inhibitor is imatinib mesylate.~~

55. (Currently Amended): A method according to claim 19, wherein said compound of formula (I) is (-)- β -L-Dioxolane-Cytidine ~~and the Ber-Abl tyrosine kinase inhibitor is imatinib mesylate.~~

56. (Currently Amended): A method according to claim 26, wherein said compound of formula (I) is (-)- β -L-Dioxolane-Cytidine ~~and the Ber-Abl tyrosine kinase inhibitor is imatinib mesylate.~~

57. (Currently Amended): A method according to claim 27, wherein said compound of formula (I) is (-)- β -L-Dioxolane-Cytidine ~~and the Ber-Abl tyrosine kinase inhibitor is imatinib mesylate.~~

58. (Currently Amended): A method according to claim 28, wherein said compound of formula (I) is (-)- β -L-Dioxolane-Cytidine ~~and the Ber-Abl tyrosine kinase inhibitor is imatinib mesylate.~~

59. (Currently Amended): A method according to claim 29, wherein said compound of formula (I) is (-)- β -L-Dioxolane-Cytidine ~~and the Ber-Abl tyrosine kinase inhibitor is imatinib mesylate.~~

60. (Currently Amended): A method according to claim 30, wherein said compound of formula (I) is (-)- β -L-Dioxolane-Cytidine ~~and the Ber-Abl tyrosine kinase inhibitor is imatinib mesylate.~~

61. (Currently Amended): A method according to claim 39, wherein said compound of formula (I) is (-)- β -L-Dioxolane-Cytidine ~~and said Ber-Abl tyrosine kinase inhibitor is imatinib mesylate.~~

62. (Currently Amended): A method according to claim 40, wherein said compound of formula (I) is (-)- β -L-Dioxolane-Cytidine and said ~~Bcr-Abl~~ tyrosine kinase inhibitor is imatinib mesylate.